ArticleMolecular cancer therapeutics2019
MTORC1/2 Inhibition as a Therapeutic Strategy for
Open access · greenAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 48 citations in OpenAlex.
- Suppression of the myofibroblastic cancer-associated fibroblast phenotype to enhance anti-PD-1 response.Journal of experimental & clinical cancer research : CR · 2026Article
- SLAP controls mTORC2 integrity via UBE3C-mediated non-degradative mLST8 ubiquitination to suppress colorectal tumorigenesis.Cell death and differentiation · 2026Article
- BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in PIK3CA-Mutant Colorectal Cancer.Molecular cancer therapeutics · 2025Article
- Wide-Field Optical Redox Imaging with Leading-Edge Detection Enables Assessment of Treatment Response and Heterogeneity in Patient-Derived Cancer Organoids.Cancer research · 2025Article
- Integrated transcriptomic and functional modeling reveals AKT and mTOR synergy in colorectal cancer.Scientific reports · 2025Article
- Selection and validation of reference genes for RT-qPCR normalization in dormant cancer cells.Scientific reports · 2025Article
- The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies.Biomedicines · 2025Review
- PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment.International journal of molecular sciences · 2024Review
- The role of PIK3CA gene mutations in colorectal cancer and the selection of treatment strategies.Frontiers in pharmacology · 2024Review
- Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease.Signal transduction and targeted therapy · 2023Review
- Review
- Bladder cancer organoids as a functional system to model different disease stages and therapy response.Nature communications · 2023Article
- Ribosome biogenesis in disease: new players and therapeutic targets.Signal transduction and targeted therapy · 2023Review
- Comprehensive investigation of the prognostic values and molecular mechanisms of syntaxin binding protein 5 antisense RNA 1 in patients with colon adenocarcinoma based on RNA sequencing dataset.Journal of Cancer · 2023Article
- Exosomes and their roles in the chemoresistance of pancreatic cancer.Cancer medicine · 2022Review
- Genomic signature of MTOR could be an immunogenicity marker in human colorectal cancer.BMC cancer · 2022Article
- Inhibition of B-cell lymphoma 2 family proteins alters optical redox ratio, mitochondrial polarization, and cell energetics independent of cell state.Journal of biomedical optics · 2022Article
- Impact of baseline culture conditions of cancer organoids when determining therapeutic response and tumor heterogeneity.Scientific reports · 2022Article
- Volumetric growth tracking of patient-derived cancer organoids using optical coherence tomography.Biomedical optics express · 2021Article
- mTORC1 stimulates cell growth through SAM synthesis and mMolecular cell · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 4 institutions in 1 country.
Stephanie L FrickeDivision of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin.
Susan N PayneUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.
Peter F FavreauMorgridge Institute for Research, Madison, Wisconsin.
Jeremy D KratzDivision of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin.
Cheri A PaschUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.
Tyler M FoleyDivision of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin.
Alexander E YuehDivision of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin.
Dana R Van De HeyDivision of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin.
Mitchell G DepkeDivision of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin.
Demetra P KorkosDivision of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin.
Gioia Chengcheng ShaDivision of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin.
Rebecca A DeStefanisDivision of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin.
Linda ClipsonMcArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin-Madison, Madison, Wisconsin.
Mark E BurkardDivision of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin.ORCID 0000-0002-4215-7722
Kayla K LemmonUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.
Benjamin M ParsonsGundersen Health System, La Crosse, Wisconsin.ORCID 0000-0002-5634-2937
Paraic A KennyGundersen Health System, La Crosse, Wisconsin.ORCID 0000-0002-5434-4402
Kristina A MatkowskyjUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.
Michael A NewtonDepartment of Statistics and Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin.
Melissa C SkalaUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.
Dustin A DemingDivision of Hematology and Oncology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin. ddeming@medicine.wisc.edu.
University of Wisconsin–Madison · USUniversity of Wisconsin Carbone Cancer Center · USGundersen Health System · USMorgridge Institute for Research · US
Funding
UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6MViral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0MOptical imaging of pancreas cancer organoids for drug development and personalized treatmentR01CA211082 · NCI · MORGRIDGE INSTITUTE FOR RESEARCH, INC. · PI SKALA, MELISSA CAROLINE · 2017 to 2021
$3.5M(PQ7) Quantitative in vivo optical imaging of tumor heterogeneityR01CA205101 · NCI · MORGRIDGE INSTITUTE FOR RESEARCH, INC. · PI SKALA, MELISSA CAROLINE · 2016 to 2020
$1.9MCellular-level Optical Metabolic Imaging to Predict Drug Response in CancerR01CA185747 · NCI · VANDERBILT UNIVERSITY · PI SKALA, MELISSA CAROLINE · 2014 to 2019
$1.6MNCI NIH HHS P30 CA014520NCI NIH HHS P30 CA086862NCI NIH HHS R01 CA185747NCI NIH HHS R01 CA205101NCI NIH HHS R01 CA211082
Abstract
PubMed holds no abstract for this paper.
Indexed as
MutationAdenineAdenomatous Polyposis Coli ProteinAnimalsBenzoxazolesCell Line, TumorClass I Phosphatidylinositol 3-KinasesCohort StudiesColorectal NeoplasmsDrug Resistance, NeoplasmFemaleHumansImidazolesMaleMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2AdenineAdenomatous Polyposis Coli ProteinAPC protein, humanBenzoxazolesClass I Phosphatidylinositol 3-KinasesdactolisibImidazolesMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2PIK3CA protein, humanPyrimidinesQuinolinessapanisertib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.